| Q33387664 | Advances in hormone replacement therapy: making the menopause manageable |
| Q51717180 | Age- and sex-related incidence of surgically treated primary hyperparathyroidism. |
| Q27013070 | An overview on the treatment of postmenopausal osteoporosis |
| Q92043490 | Assessment of the role of Trichomonas tenax in the etiopathogenesis of human periodontitis: A systematic review |
| Q40533219 | Association between bone mineral density and nonalcoholic fatty liver disease in Korean adults. |
| Q37190890 | Bioidentical hormone therapy: Nova Scotia pharmacists' knowledge and beliefs |
| Q37795801 | Bone Mineral Density in African–American Women with Symptomatic Uterine Leiomyoma |
| Q45227228 | Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women |
| Q52930339 | Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. |
| Q29042565 | Cathepsin K inhibitors for osteoporosis and potential off-target effects |
| Q40079855 | Change in the use of hormone replacement therapy and the incidence of fracture in Oslo |
| Q58123900 | Comparison Between Aspirin and Clopidogrel in Secondary Stroke Prevention Based on Real-World Data |
| Q37911560 | Consensus statements on osteoporosis diagnosis, prevention, and management in the Philippines |
| Q47933995 | Dietary Soy Protein Maintains Some Indices of Bone Mineral Density and Bone Formation in Aged Ovariectomized Rats |
| Q24803771 | Discordance in diagnosis of osteoporosis using spine and hip bone densitometry |
| Q36054925 | Does menopausal hormone therapy (MHT), exercise or a combination of both, improve pain and function in post-menopausal women with greater trochanteric pain syndrome (GTPS)? A randomised controlled trial. |
| Q44478451 | Economic evaluation of norethisterone acetate/ethinylestradiol (FemHRT) for women with menopausal symptoms |
| Q50052591 | Effect of anthocyanin-rich bilberry extract on bone metabolism in ovariectomized rats |
| Q46251429 | Effect of endogenous estradiol levels on bone resorption and bone mineral density in healthy postmenopausal women: a prospective study |
| Q46312593 | Effect of estrogen on tendon collagen synthesis, tendon structural characteristics, and biomechanical properties in postmenopausal women |
| Q36178344 | Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies |
| Q51163066 | Effect of the ethanol extract of Pleurotus eryngii on bone metabolism in ovariectomized rats. |
| Q51339531 | Effects of age on genetic influence on bone loss over 17 years in women: the Healthy Ageing Twin Study (HATS). |
| Q79830008 | Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women |
| Q58702579 | Effects of the Hormone Replacement Therapy and of Soy Isoflavones on Bone Resorption in Postmenopause |
| Q46767327 | Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women |
| Q81557242 | Epidemiology of distal forearm fractures in Oslo, Norway |
| Q51442590 | Estrogen promotes B cell activation in vitro through down-regulating CD80 molecule expression. |
| Q36658946 | Estrogen therapy for postmenopausal osteoporosis |
| Q38599114 | Estrogen-progestin therapy causes a greater increase in spinal bone mineral density than estrogen therapy - a systematic review and meta-analysis of controlled trials with direct randomization |
| Q51324558 | Eucommia leaf extract (ELE) prevents OVX-induced osteoporosis and obesity in rats. |
| Q84035888 | Fracture prevention in postmenopausal women |
| Q93501199 | Fracture prevention in postmenopausal women |
| Q35657905 | From in vivo gene targeting of oestrogen receptors to optimization of their modulation in menopause. |
| Q24247748 | Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density |
| Q35608491 | HDL cholesterol and bone mineral density: is there a genetic link? |
| Q36203216 | Hip fracture: risk factors and outcomes |
| Q24234575 | Hormone replacement for osteoporosis in women with primary biliary cirrhosis |
| Q24234784 | Hormone replacement for osteoporosis in women with primary biliary cirrhosis |
| Q42532733 | Hormone replacement therapy after the menopause--where are we now? |
| Q80552811 | Hormone replacement therapy and ovarian cancer risk: a meta-analysis |
| Q35903603 | Hormone replacement therapy and the prevention of postmenopausal osteoporosis |
| Q35198540 | Hormone replacement therapy for postmenopausal osteoporosis |
| Q44649359 | Hormone replacement therapy improves distal radius bone structure by endocortical mineral deposition |
| Q57533608 | Hormone therapy and risk of non-vertebral fracture: Geelong Osteoporosis Study |
| Q36993374 | Hormone therapy for the prevention of bone loss in menopausal women with osteopenia: is it a viable option? |
| Q36533644 | Hormone therapy: maximizing the benefits |
| Q37292711 | Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women |
| Q35092609 | Incorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan |
| Q37973239 | Individualizing osteoporosis therapy |
| Q39634884 | Isoflavones suppress cyclic adenosine 3′,5′-monophosphate regulatory element-mediated transcription in osteoblastic cell line |
| Q36535984 | Issues concerning the use of hormone replacement therapy and risk of fracture: a population-based, nested case-control study. |
| Q28083206 | Lipid metabolism disorders and bone dysfunction--interrelated and mutually regulated (review) |
| Q79752882 | Long term effects of oestrogen therapy on bone loss in postmenopausal women: a 23 year prospective study |
| Q24241279 | Long term hormone therapy for perimenopausal and postmenopausal women |
| Q24246577 | Long term hormone therapy for perimenopausal and postmenopausal women |
| Q33685435 | Long-term supplementation with young coconut juice does not prevent bone loss but rather alleviates body weight gain in ovariectomized rats |
| Q50609211 | Low bone mineral density is associated with breast cancer in postmenopausal women: a case-control study. |
| Q35919125 | Management of age-related osteoporosis and prevention of associated fractures |
| Q36152764 | Menopausal hormone therapy |
| Q26851284 | Menopause and bone |
| Q37314283 | Menopause, Reproductive Life, Hormone Replacement Therapy, and Bone Phenotype at Age 60-64 Years: A British Birth Cohort |
| Q90042427 | Muscle and Bone Mass Loss in the Elderly Population: Advances in diagnosis and treatment |
| Q79299225 | Osteoporosis |
| Q36809161 | Osteoporosis and periodontal disease |
| Q43439255 | Osteoporosis/osteopenia as an independent factor associated with periodontitis in postmenopausal women: a case-control study. |
| Q37437256 | Osteoprotective effect of hormone therapy on bone microarchitecture before impaired bone mineral density in ovariectomized rats |
| Q35757541 | Ovarian dysfunction, stress, and disease: a primate continuum |
| Q30451123 | Postmenopausal hormone therapy: an Endocrine Society scientific statement. |
| Q38082563 | Postmenopausal hormone therapy: risks and benefits |
| Q50609994 | Postmenopausal hot flushes and bone mineral density: a longitudinal study. |
| Q34296614 | Prevention and treatment of postmenopausal osteoporosis |
| Q55012766 | Primary osteoporosis in postmenopausal women. |
| Q36138452 | Response to an adequate dietary intake of vitamin D3 modulates the effect of estrogen therapy on bone density |
| Q46590586 | Risk factors for foot fracture among individuals aged 45 years and older |
| Q34899934 | Risks and benefits of hormone replacement therapy: the evidence speaks |
| Q33949479 | Safety of drugs used in the treatment of osteoporosis. |
| Q35861443 | Screening, supplements and the use of hormonal replacement therapy in postmenopausal women in a family medicine department prior to the publication of the Woman's Health Initiative report. |
| Q38824776 | Secondary prevention of osteoporosis following fragility fractures of the distal radius in a large health maintenance organization |
| Q35195120 | Similarities in acquired factors related to postmenopausal osteoporosis and sarcopenia |
| Q35202433 | Soy isoflavone intake and bone mineral density in breast cancer survivors. |
| Q34995426 | Testosterone increases bone mineral density in female-to-male transsexuals: a case series of 15 subjects |
| Q36047352 | The effect of female sex hormone supplementation on tendon in pre and postmenopausal women: A systematic review |
| Q92953011 | The effects of mumie extract on cell proliferation and enzyme expression of human osteoblast-like cells (MG63) |
| Q58707068 | The estrogen receptor 1 gene affects bone mineral density and osteoporosis treatment efficiency in Slovak postmenopausal women |
| Q35110262 | The evidence for efficacy of osteoporosis treatment in men with primary osteoporosis: a systematic review and meta-analysis of antiresorptive and anabolic treatment in men. |
| Q28263058 | The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis |
| Q35868424 | The impact of fragility fracture on health-related quality of life : the importance of antifracture therapy |
| Q37145381 | The role of hormone therapy and calcium plus vitamin D for reduction of bone loss and risk for fractures: lessons learned from the Women's Health Initiative |
| Q37277298 | The tissue selective estrogen complex: a promising new menopausal therapy |
| Q26992273 | The treatment of climacteric symptoms |
| Q36219667 | Treatment of menopausal symptoms post-Women's Health Initiative: refinement of existing treatments and development of new therapies |
| Q36045845 | Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis |
| Q50974646 | Young Coconut Juice Supplementation Results in Greater Bone Mass and Bone Formation Indices in Ovariectomized Rats: A Preliminary Study. |
| Q92782831 | Young cancer survivors have lower bone mineral density compared with healthy controls: a nationwide population-based study in Korea |
| Q81669735 | [Current role of hormone replacement therapy in the prevention of postmenopausal osteoporosis: gynecologic point of view] |
| Q79788508 | [Optimal management of patients with stress fractures and the role of the orthopedic surgeon in reducing the risk of new fractures] |
| Q81696967 | [Osteoporosis and hormone replacement therapy] |
| Q81255210 | [The more efficacious acupoints of Zusanli and Sanyinjiao than that of non-acupoints on bone mass in osteopenic ovariectomized rats] |